|
|
|
Volumn 2, Issue 7, 2004, Pages 448-454
|
|
Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
DRUG DERIVATIVE;
FLUDARABINE;
MONOCLONAL ANTIBODY;
RITUXIMAB;
TUMOR MARKER;
VIDARABINE;
AGED;
ALLOTRANSPLANTATION;
ARTICLE;
AUTOTRANSPLANTATION;
BLOOD;
CANCER STAGING;
CHEMICALLY INDUCED DISORDER;
CHRONIC LYMPHATIC LEUKEMIA;
DISEASE MANAGEMENT;
FEMALE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
IMMUNOTHERAPY;
MALE;
METABOLISM;
MIDDLE AGED;
MULTIMODALITY CANCER THERAPY;
PATHOLOGY;
PROGNOSIS;
SECOND CANCER;
TREATMENT OUTCOME;
AGED;
ANTIBODIES, MONOCLONAL;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COMBINED MODALITY THERAPY;
DISEASE MANAGEMENT;
FEMALE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
IMMUNOTHERAPY;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
MALE;
MIDDLE AGED;
NEOPLASM STAGING;
NEOPLASMS, SECOND PRIMARY;
PROGNOSIS;
TRANSPLANTATION, AUTOLOGOUS;
TRANSPLANTATION, HOMOLOGOUS;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
VIDARABINE;
|
|
EID: 30944450090
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
